GlassScriptPhysician profile
Emery A Minnard
NPI 1790887677
$182,561.89
in general payments reported to CMS, 2019-2025
30 companies · $76K in 2025
The $76K reported for 2025 was more than what 99% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,808 · 2020: $1,414 · 2021: $2,224 · 2022: $31K · 2023: $1,102 · 2024: $62K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $136K · Food and Beverage: $3,570 · Travel and Lodging: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $135,775.00 |
| Food and Beverage | $3,569.87 |
| Travel and Lodging | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evologics LLC | $132,800.00 | 2024-2025 | |
| Triad Life Sciences INC. | $17,272.53 | 2021-2022 | |
| Intuitive Surgical, INC. | $6,679.61 | 2019-2023 | Da Vinci Surgical System |
| Pacira Pharmaceuticals Incorporated | $5,199.47 | 2019-2023 | Exparel, Zilretta, Iovera |
| Biom'Up Sa | $5,050.78 | 2019 | |
| Convatec INC. | $3,240.31 | 2023-2024 | |
| Ethicon US, LLC | $1,922.51 | 2019-2025 | Vistaseal, Megadyne, Surgicel Nu-Knit |
| Biom'Up France Sas | $1,636.15 | 2020-2021 | |
| Stryker Corporation | $1,616.62 | 2019 | |
| Abbvie INC. | $1,512.06 | 2023-2025 | |
| Allergan, INC. | $1,301.74 | 2019-2022 | |
| Medtronic USA, INC. | $808.50 | 2019-2020 | |
| Medical Device Business Services, INC. | $762.06 | 2022 | |
| Mimedx Group, INC. | $647.10 | 2024-2025 | |
| Covidien LP | $406.06 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dilon Technologies, INC. | $268.03 | 2023-2025 | Hemoblast Bellows |
| Depuy Synthes Sales INC. | $242.72 | 2021-2022 | |
| Boston Scientific Corporation | $175.89 | 2024-2025 | General - Vascular Intervention, Varithena Administration Pack |
| Sientra, INC. | $173.00 | 2022 | |
| Angiodynamics, INC. | $160.70 | 2021 | |
| Bard Peripheral Vascular, INC. | $136.42 | 2024-2025 | Venclose Maven Catheter |
| Integra Lifesciences Corporation | $123.56 | 2022 | |
| Kerecis Limited | $97.54 | 2022 | |
| Davol INC. | $95.81 | 2019 | |
| Baxter Healthcare | $86.43 | 2019 | |
| Medtronic, INC. | $73.03 | 2024 | Venaseal |
| Becton, Dickinson and Company | $20.26 | 2024 | |
| Genentech USA, INC. | $20.20 | 2019 | |
| Innocoll Pharmaceuticals Limited | $17.02 | 2021 | |
| Asensus Surgical, INC. | $15.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emery Minnard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.